Elevated markers of early fibrinolysis disorder as predictors of poor 90-day prognosis in patients with aneurysmal subarachnoid hemorrhage: A large prospective cohort study.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 24 07 2023
revised: 20 09 2023
accepted: 18 10 2023
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: ppublish

Résumé

Early fibrinolysis disorder exists in aneurysmal subarachnoid hemorrhage (aSAH). We aimed to investigate the association of markers of early fibrinolysis disorder with poor 90-day prognosis in patients with aSAH. A total of 693 consecutive aSAH patients from April 2020 to December 2022 were selected from the Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage (LongTEAM) trial. Poor 90-day prognosis was defined as a modified Rankin Scale 3-6 at 90 days after discharge. D-dimer (DD) and Fibrin degradation product (FDP) levels on admission were used to assess fibrinolysis disorder and patients were classified according to their quartiles. Multivariable logistic regression analysis was used to determine the association. Of 693 patients included, 131 (18.9%) had poor 90-day prognosis. Patients in the highest quartile of DD and FDP levels had higher risk of poor 90-day prognosis than those in the first quartile (DD: adjusted odds ratio [aOR]=2.22, 95% confidence interval [CI], 1.13-4.36, p = 0.021; FDP: aOR=2.87, 95% CI, 1.48-5.58, p = 0.002), after adjusting for potential risk factors. Meanwhile, a linear dose-response relationship between DD and FDP and poor 90-day prognosis was found. Subgroup analysis showed that DD and FDP were consistently associated with poor 90-day prognosis across subgroups, and no intergroup interaction was found. Interestingly, the associations of DD and FDP with poor 90-day prognosis were more significant in low-grade aSAH patients. Elevated markers of early fibrinolysis disorder, including DD and FDP on admission, were associated with poor 90-day prognosis in aSAH patients.

Identifiants

pubmed: 38847809
pii: S1052-3057(23)00456-1
doi: 10.1016/j.jstrokecerebrovasdis.2023.107433
pii:
doi:

Substances chimiques

Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107433

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no personal, financial, or institutional interest in any of the materials or methods used in this study or the findings specified in this paper.

Auteurs

Tu Li (T)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Jun Zhang (J)

Department of Neurosurgery, Peking University International Hospital, Beijing, China.

Runting Li (R)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Fa Lin (F)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Yu Chen (Y)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Jun Yang (J)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Heze Han (H)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Ke Wang (K)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Yitong Jia (Y)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Yang Zhao (Y)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Peking University International Hospital, Beijing, China.

Shuo Wang (S)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Stroke Center, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.

Yuanli Zhao (Y)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, Peking University International Hospital, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Stroke Center, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.

Xiaolin Chen (X)

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Stroke Center, Beijing Institute for Brain Disorders, Beijing, China; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China. Electronic address: chenxiaolin@bjtth.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH